RxDoctor Payments Data

Karen Piren

Psychiatric/Mental Health · Hampton, NJNPI 1316165095

Payments from drug & device makers

$936in general payments, 2019–2025

Across 49 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$254
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$168
  • AbbVie$122
  • Indivior Inc.$121
  • E.r. Squibb & Sons, L.L.C.$89
  • Alkermes, Inc.$68
  • plus $114 from 3 others

What the payments were for

  • Food & beverage$936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$936 in reported general payments places this provider in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$7,752
Medicare patients
21
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate33$88,065
CaplytaLumateperone Tosylate15$20,840
SaphrisAsenapine Maleate15$4,954
Chlorpromazine Hcl17$4,478
Haloperidol Decanoate67$1,832
Lurasidone Hcl13$1,266
Benztropine Mesylate81$1,201
Haloperidol55$1,117
Olanzapine96$1,101
Ziprasidone Hcl26$982
Paliperidone ErPaliperidone12$882
Aripiprazole39$807
Hydroxyzine Hcl20$609
Quetiapine Fumarate47$570
Trazodone Hcl70$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$51$88,06533 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$168$20,84015 claims
AbbVieSaphris$122$4,95415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Hampton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →